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INTRODUCTION

Research shows that people who are tall and beautiful tend to be more successful
and earn more on average than their shorter, less beautiful counter parts.2 Unfair as
it may be, beauty, brains, and a tree-like verticality have arguably tilted the odds of
success in favor of a select few for eons. Recent scientific advancements, however,
may soon level the genomic playing field. The American Bar Association recently
published an article about a new gene-editing technology known as CRISPR which
is short for "clustered regularly interspaced short palindromic repeats." CRISPR
[guided by RNA] can be directed to make
"and .. . associated protein (Cas) ...
specific cuts in DNA, which can then allow the deletion and/or insertion of desired
sequences," making lab-made human DNA and genetically modified embryos
("GMEs") an imminent reality.' This scientific breakthrough has the potential to rid
humanity of life threatening genetic diseases like Tay-Sachs, Huntington's disease,
genetic forms of cancer, and any other type of disease that is passed on through
DNA. 5
The field of genetic research has been significantly impacted by CRISPR
technology. Prior to CRISPR, editing human DNA was incredibly expensive and
inefficient, with systems costing anywhere from $500 to $5,000.6 A comparable
CRISPR system costs around $30.' Prior technology only allowed for the editing of
one strand of DNA at a time, however, CRISPR allows for simultaneous editing of
all like strands, which significantly decreases the amount of time needed for the
overall process.' CRISPR has made DNA editing more affordable and efficient,
opening the door to genomic modification and testing on an unprecedented scale.'
With this technology at their fingertips, parents will have the power, not only to make
their children healthier, but also prettier, taller, and more intelligent.
To that end, CRISPR has the potential to alter the course of human evolution by
editing the human "germ line" which is the egg and sperm that combine to create an
embryo.io Those edits can then be passed on to future generations, allowing scientists
2 Sean Gregory, Why Tall People Are Happier Than Short People, TIME (Jul. 29, 2009),
http://content.time.com/time/business/article/0,8599,1913256,00.html [https://pernaccV2QB-XJGD];
Ray Williams, GoodLooks Can Get You That Job, Promotion and Raise, FIN. POsT (Sep. 8,2011,6:31
PM), https://business.inancialpostco/executivecareers/good-looks-cn-get-you-hat-job-promotionand-raise [https://permacc/6TFX-J2K6].
3 Brendan Parent, CRISPR Lit the Fire: Ethics Must Drive Regulation of Germline Engineering,
SCITECH LAw., Fall 2016, at 18.
4
Id at 18-19.
s Id at 18, 20; Antonio Regalado, Engineeringthe Perfect Baby, MIT TECH. REV. (Mar. 5, 2015),
[https://perma.cc47MFhttps://www.technologyreview.com/s/535661/engineering-the-perfec-baby
AFY2].
* Sarah Ashley Bamett, Comment, Regulating Human Germline Modification in Light of CRISPR,
51 U. RICH. L. REV. 553, 565 (2017) (discussing CRISPR's distinguishing features from previous DNA
modifying technologies).
7
id
Id at 563.
9
See Robert Sanders, Simple Technology Makes CRISPR Gene Editing Cheaper, BERKELEY NEWS
(Jul. 23, 2015), http://news.berkeley.edu2015/07/23/simple-technology-makes-crispr-gene-editingcheaper/ [https://perma.ccl29TY-SWNQ].
o Regalado, supra note 5.
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to alter mankind's evolutionary path." Naturally, CRISPR's potential is alluring for
a variety of reasons. This technology, however, is still relatively new, and a majority
of the scientific community currently agrees that CRISPR should not be used to edit
viable human embryos until they are more certain that it can be used safely.' 2 Despite
a lack of consensus in the scientific community, the use of CRISPR technology is
moving forward. In 2015, Chinese researchers modified human embryos with
CRISPR, in an attempt to cure a fatal blood disease known as beta thalassemia.1 3
Moreover, in the U.S., a 2015 Pew Research survey revealed that 46% of American
adults are in favor of genetically modifying human embryos as long as the procedure
is done to rid the embryo of heritable disease.1 4 Once it is safe enough to use,
CRISPR technology will likely get the green light from American policy makers.
Thus, the question is not when CRISPR will affect American life, but how American
policy makers should regulate this technology.
The use of CRISPR in human germline editing is bound to raise significant legal
issues in the U.S. This note will discuss policy concerns in two parts. Part I will
address whether genetically modified human embryos can and should be patented in
light of the Thirteenth Amendment. Any patent on an embryo would arguably last
far beyond the birth of the child, thus creating property rights in a human being. Part
I will ultimately suggest that a modified and narrowly tailored form of patent
exhaustion should apply to patents drawn to CRISPR modified embryos. Part II will
discuss the safety and ethical issues associated with CRISPR technology. This Part
will suggest that as in any form of risky specialized medicine, only those who are
trained and licensed should be able to use CRISPR technology, and finally, explain
why CRISPR technology should not be likened to eugenics. Part II will conclude that
there is nothing new under the sun, and CRISPR is just a more efficient way of doing
what humans have been doing naturally for eons-selecting desirable offspring
through sexual selection.

1.

PATENTABILITY OF GENETICALLY MODIFIED EMBRYOS

There are four substantive requirements which must be met for an invention to
qualify as patentable," and it is highly likely that CRISPR modified embryos meet
the standard. In order to be patentable, an invention must be: patentable subject
matter, useful, novel, and nonobvious."' Precedent shows that cultured human cell
lines qualify as patentable material. In Moore v. Regents of the University of
California, the court stated that "[h]uman cell lines are patentable because
'[1]ong-term adaptation and growth of human tissues and cells in culture is
"See id
12
See Tanya Lewis, There Are Really Good Reasons Why We Should-and Shouldn't-Genetically
Engineer
Human
Embryos,
Bus.
INSIDER
(Dec.
4,
2015,
10:30
AM),
http://www.businessinsider.com/arguments-for-and-against-editing-human-embryos-2015-12
[https://pema&cc/MB32-4K33].
1 Id
4 See Regalado, supra note 5.
&

1 LYDIA PALLAS LOREN & JOSEPH Scurr MILLER, INTELLECTUAL PROPERTY LAW: CASES

MATERIALS
165 (5th ed. 2017).
6
Id
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difficult--often considered an art.. .,' and the probability of success is low." 7 Thus,
if mere cultured human cell lines are patentable material, surely CRISPR edited
strands of DNA which create entirely new gene lines would qualify as patentable
material as well. To that end, this paper will assume that CRISPR modified embryos
are also useful, novel, and nonobvious, thus allowing them to qualify for patents
through the Patent Act.' 8
If an inventor meets these requirements, she may apply for a patent under the
Patent Act which would give her the "right to exclude others from making, using,
offering for sale, or selling the invention."" Thus, the Patent Act gives inventors the
right to exclude.2 o Such a right is arguably "the hallmark of a protected property
interest." 2' In fact, the Supreme Court has stated that the right to exclude is "one of
the most essential sticks in the bundle of rights that are commonly characterized as
property,"" meaning that the Patent Act grants powerful property interests to the
inventor who is able to obtain a patent over her invention.
The landmark case of Diamond v. Chakrabarty, decided in 1980, assessed a
scientist's claim of ownership over a novel strain of bacterium he created, holding
that under 35 U.S.C. § 101, man-made microorganisms were not outside the scope
of patentable subject matter.2 3 Chakrabarty was a scientist who had applied for a
patent after developing a special type of bacteria that essentially broke down crude
oil--an incredible feat for tackling issues like oil spills in the Gulf and other similar
disasters, and a feature that no naturally occurring bacteria possesses.24 Needless to
say, Chakrabarty had created a very useful bacteria, one that he undoubtedly hoped
to make a profit off of, and thus wished to have property rights over. Chakrabarty's
application, however, was rejected by a patent examiner, and the rejection was
affirmed by the Patent Office Board of Appeals, holding that under § 101, living
things were not patentable." The Supreme Court rejected this view, concluding that
§ 101 did not specifically exclude living things from patentable subject matter.26 The
Supreme Court explained that legislative intent showed that Congress wanted
"statutory subject matter to 'include anything under the sun that is made by man. '27
Thus, the Court determined that Chakrabarty had created: "[A] new bacterium with
markedly different characteristics from any found in nature and one having the
potential for significant utility. His discovery is not nature's handiwork, but his own;
accordingly it is patentable subject matter under § 101."28 Following this decision,

" Moore v. Regents of Univ. of Cal., 793 P.2d 479,492-93 (Cal. 1990) (quoting U.S. CONG., OFFICE
OF TECH. ASSESSMENT, OTA-BA-337,

NEW DEVELOPMENTS IN BIOTECHNOLOGY: OWNERSHIP OF

HUMAN TISSUES AND CELLs-SPECIAL REPORT 33 (1987)).
'aSee 35 U.S.C. §§ 101-103 (2012).
19 1d § 154.
2 Id

Coll. Say. Bank v. Fla. Prepaid Postsecondary Educ. Expense Bd., 527 U.S. 666, 673 (1999).
* Kaiser Aetna v. United States, 444 U.S. 164, 176 (1979).
* Diamond v. Chakrabarty, 447 U.S. 303, 305, 309 (1980).
24
d at 305.
25
d at 306.
SId at 318.
SId at 309 (quoting S. REP. No. 82-1979, at 5 (1952) and H.R. REP. NO. 82-1923, at 6 (1952)).
28d at310.
21
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the Patent and Trademark Office ('PTO") decided it would begin allowing patents
for "nonnaturally occurring, non-human multicellular living organisms, including
animals, to be patentable subject matter within the scope of 35 U.S.C. 101."29
Despite the PTO's stance that it would allow patents on "nonhuman multicellular
living organisms," in 2001 it granted the entire spectrum of patent rights to a scientist
using human stem-cells. 30 Therefore, current PTO rules and Supreme Court
precedent appear to fully allow an inventor to hold patent rights over living human
organisms. Such precedent would likely allow for embryos genetically modified by
CRISPR to be encompassed in the range of patentable, living, human organisms.
Since CRISPR technology allows for insertion or deletion of discrete bits of DNA in
a germ-line," the new DNA strand created is man-made, like the bacterium in
Chakrabarty.Further, CRISPR can create sequences of DNA which arguably would
not occur on their own in nature,32 as was the case in Chakrabarty,and such creations
would without a doubt have utility if scientists were able to remove diseases such as
Tay-Sachs from the genetic code of an embryo. Thus, CRISPR genetically modified
embryos appear to fit nicely into the framework of patentable material already
recognized by the Supreme Court and the PTO.
A. The Thirteenth Amendment's Effect on the Patentabilityof GMEs

.

Even if CRISPR modified embryos are able to overcome the hurdle
of patentability, a more serious concern looms over the future of this
technology-namely, whether or not issuing such patents would be a violation ofthe
Thirteenth Amendment of the United States Constitution. The Thirteenth
Amendment abolished slavery, stating: "Neither slavery nor involuntary servitude,
except as a punishment for crime whereof the party shall have been duly convicted,
shall exist within the United States, or any place subject to their jurisdiction."" Much
of the legal community interpret the Thirteenth Amendment to have abolished
"chattelism"-the holding of property in another human being.34 To that end, there
are some legal commentators who claim that the only type of property rights
abolished by the Thirteenth Amendment were those which created slavery situations
"akin to African slavery."" However, historical context suggests that the Thirteenth
Amendment was established to eliminate the ability for one person to hold any
property rights in another human being.36 In fact, "by 1865 'virtually everyone . .
29
U.S. PATENr & TRADEMAIUC OFFicE, MANUAL OF PATENT EXAMINING PROCEDURE § 2105 (9th
ed. Rev. 8, Jan. 2018), https://www.uspto.gov/web/offices/pac/mpeps2105.html [https://perma.ccQ56FWKHW ].
I See John Miller, Comment, A Call to Legal Arms: Bringing Embryonic Stem Cell Therapies to
Market, 13 ALB. LJ. Sc. & TECH. 555, 561-62 (2003).
" See supra notes 4, 10 and accompanying text.
32
See Regalado, supra note 5.
33
U.S. CONsT. amend. XIII, §§ 1-2.
1 See, e.g., Esther Slater McDonald, Note, Patenting Human Life and the Rebirth of the Thirteenth
Amendment, 78 NOTRE DAME L. REv. 1359, 1373-74 (2003).
35 Jonathan Grossman, Comment, Human Embryos, Patents, and the Thirteenth Amendment, 55 KAN.
L. REv. 731, 760 (2007).
36 See McDonald, supra note 34, at 1371-72.
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understood slavery as chattelism' the idea that human beings can be property." 3 1
Thus, it was the "abhorrence of [the idea of human beings held as property that]
fueled the abolitionist movement."'
Moreover, statements from Representative Green Clay Smith, a Unionist Party
U.S. Congressman from Kentucky," shed light on thoughts and circumstances
surrounding the passage of the Thirteenth Amendment.'" In his desire to see the
Thirteenth Amendment passed, Rep. Smith stated: "We intend to establish the great
truth that man cannot hold property in man."' Smith represented the Unionist Party
from 1862 until 1866 and was thus square in the middle of the controversy over
slavery. 42

Additionally, Esther McDonald's analysis of the Thirteenth Amendment, in her
note published in the Notre Dame Law Review, confirms that the Thirteenth
Amendment was certainly intended not just to prohibit black slavery, but all types of
human slavery. In her note, McDonald asserted the following:
The debates over the Civil Rights Act of 1866 and the Fourteenth
Amendment further establish that the Thirteenth Amendment banned
chattelism. Believing that the Thirteenth Amendment abolished
chattelism and guaranteed basic human rights, several congressmen
moved to pass civil rights legislation under the authority of the Thirteenth
Amendment Other congressmen disagreed with that expansive
interpretation, believing that the Thirteenth Amendment secured only "the
right not to be held in bondage." These congressmen argued that "slavery
was defined as chattelism rather than as a denial of all political and civil
rights." To protect civil rights, claimed these congressmen, the country
would have to pass a second amendment, the Fourteenth. Therefore, even
congressmen restricting the Thirteenth Amendment to its narrowest

interpretation agreed that the Amendment prohibited property ownership
of humans.43
Thus, after assessing the viewpoints of both those who were in favor of
interpreting the Thirteenth Amendment broadly and those who wished to interpret it
narrowly, there was at least a clear consensus regarding the fact that the Thirteenth
Amendment forbade anyone from holding property rights in another human.
Following the passage of the Thirteenth Amendment, American jurisprudence
clarified some confusion surrounding the Amendment. In the Slaughter-House
3

Id (quoting HERMAN BELz, A NEW BIRTH OF FREEDOM: THE REPUBUCAN PARTY AND

FREEDMEN'S RIGrrs 1861 TO 1866 121 (2000)).
3 Id at 1372.
" See generally, Berry Craig, How Four Kentucky Congressmen Helped End Slavery,
AM),
https//www.courier9:54
2015,
29,
(Jan.
COURIER-JOURNAL
journal.com/story/opinion/contributors/2015/01/29/four-kentucky-congressmen-helped-endslaveryt22519043/ [httpsi//perma.ccN6WW-9UB5] (discussing the role of Green Clay Smith, among
others, in helping to pass the Thirteenth Amendment).
4 See McDonald, supra note 34, at 1373-74.
4' Id. at 1373.
42
See BiographicalDirectory of the United States Congress: Smith, Green Clay, CONORESS.GOV,
http://bioguide.congress.gov/scripts/biodisplay.pl?index=S000544 [httpsJ/permacc;/A565-AFKR].
' McDonald, supranote 31, at 1374 (footnotes omitted).
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Cases, petitioners claimed that a monopoly over slaughterhouses, created by state
statute, violated the Thirteenth Amendment because in order to earn a living they
would be subjected to involuntary servitude." The Court concluded that the use of
the word servitude in the Amendment had the "obvious purpose" of forbidding "all
shades and conditions of African slavery.4 s Finally, the Court further clarified the
purpose of the Thirteenth Amendment by stating that the Amendment "forbids any
other kind of slavery, now or hereafter."
Since it appears as though both legislative history and popular American thought
at the time the Thirteenth Amendment was passed supports the idea that slavery was
chattelism, and that the goal ofthe amendment was to abolish chattelism over human
beings, this paper will continue to analyze how patents, should apply to CRISPR
modified embryos based upon that premise. Roe v. Wade rejected the idea that
embryos had personhood status under the Constitution;` thus as of now, a patent
over an embryo would likely not violate the Thirteenth Amendment. There is,
however, a potential problem with how broadly current patent law would apply to
embryos. Law students, Esther McDonald and Jonathan Grossman, argue opposite
positions on whether patents drawn to embryos would violate the Constitution.' This
section proposes that the law likely finds a middle ground somewhere in between
McDonald and Grossman's arguments.
McDonald argues that life begins at conception and thus embryos should have
human status attributed to them."' Therefore, under McDonald's premise, any patent
drawn on an embryo would do violence to the Thirteenth Amendment because such
a patent would grant property rights over a human being.so In contrast, Grossman
addresses the fact that the United States does not, at this point in time, recognize
embryos as human beings, and therefore, under his analysis any patent drawn on an
embryo would clearly not violate the Thirteenth Amendment." It is likely, however,
that both McDonald and Grossman have fallen short in their analysis of how patent
law would apply to genetically modified embryos. It is true that the U.S. does not
give embryos legal personhood status," and thus any patent drawn to an embryo
would likely not be in violation of the Thirteenth Amendment. This argument,
however, is short-sighted in that it fails to recognize the broad scope of patent law.
In reality, the goal of implanting a genetically modified embryo is that at some point
the embryo will attain viability. Under Planned Parenthoodv. Casey, viability is
recognized as: "[T]he time at which there is a realistic possibility of maintaining and
nourishing a life outside the womb, so that the independent existence of the second
life can in reason and all fairness be the object of state protection that now overrides
" Slaughter-House Cases, 83 U.S. (16 Wall.) 36, 60, 66 (1872).

45

Id at 69.

* Id at 72.
47
Roe v. Wade, 410 U.S. 113, 158 (1973).
a Compare Grossman, supra note 35, at 760 (arguing that patents on human embryos do not implicate
the Thirteenth Amendment), with McDonald, supra note 34, at 1381-86 (arguing that patents on human
embryos
violate the Thirteenth Amendment).
4
McDonald, supra note 34, at 1366-70.
5
0Jd at 1386.
s Grossman, supra note 35, at 753, 755.
*Roe, 410 U.S. at 157-58.
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the rights of the woman."" Thus, Casey seems to suggest that the Constitution
confers some human rights on the unborn beginning at viability. This creates a sort
of grey area for the patentability of embryos since the Thirteenth Amendment forbids
holding property rights in a human being. Yet, after Casey it is hard to nail down
whether viable embryos are considered human beings, or whether embryos are
merely granted some form of human being status that protects them from death, but
perhaps not from ownership. Regardless of whether viable embryos should be
excluded from patentability due to their human-being status, one thing is
certain-viable embryos have a hopeful future, otherwise known as birth.
Successfully implanted GMEs have the potential to become genetically modified
babies who have the full status of personhood under the Constitution.' Accordingly,
genetically modified babies certainly come under the protection of the Thirteenth
Amendment. Therefore, the problem lies in the fact that most patents last for up to
twenty years;s" thus an inventor who holds a patent over the DNA/germlines in a
GME would inevitably still hold rights in those germlines once the baby is born.
Such a scenario would mean that a patent holder could hold property rights in a
human being, thus violating the Thirteenth Amendment.
B. ExistingPatentLaw Must be Modified
The solution to this problem should not be to exclude GMEs from patentability
altogether, but simply to force exhaustion of the patent once implantation of the
embryo into a womb has occurred. It would not be wise to eliminate GMEs from
patentability completely, since innovation is spurred by the patent system, which
encourages inventors to spend money and time on their creations in hopes that they
will be able to obtain ownership over their invention and profit off its success.56
Without this system in place, one who subscribes to a more Hobbesian view of the
world could argue that inventors would be less motivated to spend vast amounts of
time and energy on their work since anyone could rip them off in the end." To that
end, CRISPR modified embryos will certainly require incredible amounts of time,
money, resources, and scientific genius to reach a point where society feels safe
enough to incorporate this technology into the human race since CRISPR allows for
modification of the germline, which is heritable through procreation.s" Thus, what
one generation of scientists do today through CRISPR may affect the world for
generations to come. It is crucial to incentivize the best and brightest to invest all
they can into CRISPR technology since it has the potential to alter the course of
' Planned Parenthood of Southeasten Pa. v. Casey, 505 U.S. 833, 870 (1992).
54
See U.S. CoNsT. amend. XIV, § 1.
ss
Frequently
Asked
Questions on
Patents
and Exclusivity, U.S.
FDA,
https/www.fda.gov/Dnjgs/DeveopmentApprovalProcess/uc07903l.htm [https://pennacc2LE2-5BUC].
5 See Grossman, supra note 35, at 767 ("[TJhc patent system serves as a reward for innovation and
an inducement for commercialization of new technologies.").
' Those subscribing to the Hobbesian view believe "the state is so essential to the creation and
maintenance of social order," and that it acts "as a third party that stands ready to punish those who do
not respect their neighbor's rights." Andrew Rutten, Anarchy, Order, and the Law: A Post-Hobbesian
View, 82 CORNELL L. R~v. 1150, 1150 (1997).
' See supra note 10-14 and accompanying text.
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human evolution. Patents should be drawn to inventors using CRISPR technology,
however, those patents must be limited in nature.
Unfortunately, current patent law does not create a workable framework for the
legal issues presented by genetically modified embryos. Again, the problem is that
patents currently last for up to twenty years," which, when applied to the germline
of a GME, would last past the point of birth. The Born-Alive Infants Protection Act
of 2002 confers full personhood to any member of the species homo sapiens who is
born alive:
In determining the meaning of any Act of Congress, or of any ruling,
regulation, or interpretation of the various administrative bureaus and
agencies of the United States, the words "person", "human being",
"child", and "individual", shall include every infant member ofthe species
homo sapiens who is born alive at any stage of development.6 0

Thus, any patent drawn on a GME must exhaust perhaps before viability, but
certainly before birth, in order to avoid both a violation of the Thirteenth Amendment
and the PTO's rule that it will not issue patents drawn to human beings. 6 1
While patent exhaustion is the best solution current patent law has to remedy the
situation created by a patent on a GME's germline/DNA, it is currently too broad in
its application to living organisms to truly fix the constitutional problems created by
patenting embryos. 62 The Court in Bowman v. Monsanto explains the doctrine of
patent exhaustion as the following: "[P]atent exhaustion limits a patentee's right to
control what others can do with an article embodying or containing an invention.
Under the doctrine, 'the initial authorized sale ofa patented item terminates all patent
rights to that item.""" In Bowman, a firmer purchased genetically modified soybean
seeds over which Monsanto held a patent." The farmer then reproduced the seeds
through planting and harvesting.65 Upon discovering the farmer's practices,
Monsanto filed suit against him, claiming patent infringement." In its assessment of
the doctrine of patent exhaustion, the Supreme Court held that though a patent may
exhaust, such exhaustion merely grants a purchaser the freedom to use or resell, but
not the ability to manufacture or reproduce the patented creation.6 1
Leaving any property right on the table over germlines/DNA after birth would be
a violation of the Thirteenth Amendment because the patent holder could exclude a
human being for up to twenty years from reproducing her patented germline. This
would mean that the patentee could be restricted from having her own children
because the patented germline could be reproduced in them. She could also be kept
from having her cells extracted and then grown in a lab for cancer treatment research
" See supra note 55 and accompanying text.
6*1 Born-Alive Infants Protection Act of 2002 § 2(a), I U.S.C. § 8(a) (2012).
McDonald, supra note 34, at 1361.
' See Bowman v. Monsanto Co., 569 U.S. 278, 284-86 (2013).
a Id. at 283 (quoting Quanta Comput, Inc. v. LG Elecs., Inc., 553 U.S. 617, 625 (2008)).
*Id at 281-82.
5
6 Id at 282.
6 Id
67
See id at 289.
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or other similar procedures. Such a result would be clearly unacceptable since both
congressional and jurisprudential history confirm that the Thirteenth Amendment
forbids chattelism or property ownership in human beings." Thus, in order to

preserve the patentability of GMEs, the doctrine of patent exhaustion must be
modified and narrowed as it applies to living, human organisms. The doctrine of
patent exhaustion as applied to living, human organisms, should allow for the
termination of any and all property rights after the GME is implanted in a womb in
order to avoid conflict with the mother's rights over her pregnancy; however, any
and all rights must terminate before birth in order to avoid violating the Thirteenth
Amendment and the PTO's rule disallowing patents over human beings.
C CurrentHHS Guidelines and the PotentialEffect on CRISPR Technology
As applied to CRISPR modified embryos, a modified version of patent
exhaustion would allow for innovation, while also alleviating any possible
Thirteenth Amendment violations. Current events, however, have shifted drastically
under the new U.S. President, Donald Trump. If this paper failed to include and
analyze the new changes facing the scientific community under Trump's leadership,
this paper would be incomplete. Recently, the Department of Health and Human
Services released a polarizing strategic plan for 2018-2022.69 Most notably, the plan
attributed human status to embryos in utero.o In reference to the agency's goal of
serving Americans, the original draft stated that the agency's goal was to serve
"Americans at every stage of life, from conception."7 1
However, the initial draft alarmed a number ofpeople in the scientific community
who feared that the HHS under Trump would limit scientists' ability to work with
embryos, thus setting back progress for areas of research and practice such as in vitro
fertilization, stem cell therapy, and of course, CRISPR modifications.7 In response
to the proposed HHS strategic plan changes, a recent article by MIT Technology
Review stated:- "Researchers are concerned that any one of the new advances could
prompt steps by the Trump administration to limit science, similar to President
George W. Bush's restrictions on federal funding for stem-cell research in 2001."7
To that end, many in the scientific community believe it may be in their best interest
to postpone making any great strides with CRISPR technology and the like until the
end of the Trump administration in order to avoid bringing unwanted scrutiny to the
projects they know are politically controversial. Though currently there is no
official regulation from the Trump administration that would thwart the progress of
' McDonald, supra note 34, at 1374.
6
Introduction: About
HHS
Strategic
Plan,
FY
2018-2022,
HHS.GOV
https://www.hhs.gov/about/strategic-plan/introduction/index.html https://perma.cc/C7YK-U7NW]; see
also Emily Mullin, Under Trunp, Biologists FearPoliticalRisks ofControversialResearch, MIT TECH.
REv. (Nov. 9, 2017), hUps://www.technologyreview.comf/s/609323/under-trump-biologists-seek-a-lowprofile-for-controversial-research/ [https:17pennacdWSK-24MR].
7 See Mullin, supra note 69.
7
Introduction:About HHS StrategicPlan, FY 2018-2022, supranote 69.
' See Mullin, supranote 69.
7
Id
74
See id
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embryonic research, the scientific community will likely proceed slowly with
CRISPR and the like until there is more certainty about how legislators will respond
to embryonic research."
For instance, as of now scientists in the United States have a type ofself-governed
rule that they will not grow embryos in a lab for more than two weeks, while other
countries enforce this standard through law." Some in the scientific community
would like to see the time spent growing embryos in a lab extended past this
two-week marker, however, during a recent meeting at the National Academies of
Science in Washington, D.C., there was push back on this idea due to fear of
unwanted attention from legislators." During the meeting, a panel of experts
suggested that disagreement over whether to allow embryos to grow for more than
two weeks should be settled by "carrying out a study and making
recommendations."' According to the MIT Technology Review article, in response
to this suggestion:
Alta Charo, a professor of law and bioethics at the University of
Wisconsin at Madison, said ... that openly debating the rule could "invite
some unwanted attention" from the Trump administration and state
legislators. "My overriding concern is that this discussion and any action
in this area is going to trigger state legislation," she told members of the
National Academies' committee on technology, policy, and law.'
Thus, theoretically, while advancement in CRISPR technology is a clear and
present reality, practically speaking, it is likely that any significant progress will, for
now, be undisclosed by the scientific community, or simply not occur until a new
administration takes the reigns in Washington.'
I. SAFETY AND ETHIcAL CONCERNS REGARDING CRISPR

How CRISPR will fit into the framework of patent law is merely one of the many
legal issues created by this new technology. Additionally, public policy makers must
determine how to regulate the use of CRISPR in the United States. At this point in
time, the majority of the scientific community, including those who engineered the
technology, are in agreement that CRISPR presents serious safety and ethical
issues."' The fear regarding safety, however, has not stopped the onward march of
some scientists who are willing to make riskier moves. Recently, researchers at a
university in China used CRISPR on a non-viable human embryo in an attempt to
remove the gene responsible for a fatal blood disease known as beta-thalassaemia,
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however, the results gave rise to much concern in the scientific community.8 There
were a "surprising number of 'off-target' mutations assumed to be introduced by the
CRISPR/Cas9 complex acting on other parts of the genome."83 The results showed
that unintended mutations from CRISPR were far worse in the human embryo than
they had been in prior studies using "mouse embryos or human adult stem cells."
Thus, the unintended consequences are still widely unknown. In addition to the
problems scientists know CRISPR may cause, some fear that CRISPR "might stay
in cells after the intended cuts are complete and continue to edit similar off-target
sequences." 8

5

TIME magazine published an article covering the Chinese university's research
in the spring of2015."6 The article outlined a piece published in National Geographic
by science writer Carl Zimmer, stating:
The experiment "came out poorly," Zimmer says; in some cases,
DNA was placed in the wrong spot and "off-target" mutations were
discovered in the DNA. As Zimmer reports, scientists behind the CRISPR
technique are arguing it was not ready for use. Jennifer Doudna, one of
the creators of CRISPR, told Zimmer: "Although it has attracted a lot of
attention, the study simply underscores the point that the technology is not
ready for clinical application in the human germline. And that application
of the technology needs to be on hold pending a broader societal
discussion of the scientific and ethical issues surrounding such use.""
Many in the scientific community echoed Zimmer's concerns, however,
following reports of the controversial research, a Chinese source reported at least
four different groups were "pursuing gene editing in human embryos."' Yet, despite
the fact that there is widespread consensus regarding the need to hold off on CRISPR
experiments using human embryos, CRISPR is currently completely unregulated in
the United States, giving scientists a lot of ethical wriggle room." Though the
Dicky-Wicker Amendment prohibits the distribution of federal funding for any
research or procedures related to embryonic modification, this merely restricts
individuals from working with CRISPR using federal funding. 0 Additionally, the
National Institute of Health refuses to fund research or procedures involving genetic

- David Cyranoski & Sara Reardon, Chinese Scientists Genetically Modify Human Embryos,
NATURE NEWS & COMMENTr (Apr. 22, 2015), httpJ/www.nae.com/news/chinese-scientistsgenetically-modify-hwnan-embryos-1.17378 [https://perma.co9PFP-X6RQ].
w Id

" Parent,supra note 3, at 19.
a Alexandra Sifferlin, Chinese Researchers Modify Human Embryos in Swudy, TIME HEALTH (Apr.
23,2015), http://time.com/3832908/crispr-embryos/ [https://perma.cdJWW8-HRTP].
K Id
' Kevin Loria, Chinese Scientists Just Admitted to Tweaking the Genes of Human Embryos for the
First Time in History, Bus. INSIDER (Apr. 22, 2015, 4:53 PM), http/www.businessinsider.com/chinesescientists-genetic-modification-human-embryo-ctispr-2015-4 [https://pemaccf7LSY-H6VK].
* Barnett, supra note 6, at 576.
9 See id
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modification of the human genome," the ability for scientists to conduct CRISPR
research through private funding is left unregulated.' Due to the magnitude of
CRISPR's possible effect on the human race and the safety issues it currently
presents, CRISPR should be heavily regulated in the United States, preferably
through an international treaty.'
A. The FDA and State Medical Boards
Throughout the period in which GMEs are non-implantable, the FDA will be in
the prime position to regulate scientific progress and research regarding CRISPR
technology. If and when CRISPR is safe enough to use on implantable embryos,
however, regulation by the FDA alone will not be sufficient to oversee CRISPR use.
As with in vitro fertilization, and any other obstetric medical procedure, Congress
should grant state medical boards the ability to regulate the process by requiring and
granting licensure and requiring licensing renewal at appropriate intervals." The job
of the state medical board is to protect American citizens from "incompetent,
unprofessional, and improperly trained physicians[,]"' putting state medical boards
in the perfect position to regulate CRISPR use once the technology is ready to use
on implantable embryos.
State medical boards implement a very formal process for anyone wishing to
practice medicine in the United States,' and that same process should apply to
anyone wishing to practice medicine using CRISPR technology. Anyone wishing to
practice medicine must first seek approval from the state in which that individual
wishes to practice.' States typically have statutes known as medical practice acts,
which "govern the practice of medicine and specify the responsibilities of the
medical board in regulating that practice."" Licensed medical practitioners must
practice medicine in accordance with these statues, and "[s]tate medical boards
establish the standards for the profession through their interpretation and
enforcement of this act."" State medical boards assess would-be medical
practitioners for licensure by evaluating their overall educational background,
including undergraduate and medical school, along with other significant factors

9 Evita V. Grant, FDA Regulation of Clinical Applications of CRISPR-CAS Gene-Editing
Technology, 71 FooD & DRUG LJ. 608, 609 (2016).
* See Barnett, supra note 6, at 577.
'This paper will not address an international treaty; however, it stands to reason that since 21"
century humans are global travelers with the ability to choose mates from different countries, and since
CRISPR modifies the germline, creating changes which can be passed on to future generations, an
international treaty would be the best way to manage this new technology.
9 For an explanation for the process by which state medical boards grant licensure, see Drew Carlson
& James N. Thompson, The Role of State Medical Boards, 7 ViRTUAL MENTOR 311 (2005),
https://joumalofethics.ama-assn.org/sites/journalofethics.ama-assn.org/fles/2018-07/joe-0504.pdf
[https://perma.cc/85EX-97HX].
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such as personal character and work history.'00 Finally, those wishing to obtain a
medical license must also pass the 3-step United States Medical Licensing
Examination, also known as the USMLE, which was created by "The Federation of
State Medical Boards of the United States, Inc., and the National Board of Medical
Examiners (NBME)," before they can obtain medical licensure.'r Thus, since these
regulations are already in place and functioning quite efficiently, it would be
inefficient to create a new regulatory system for CRISPR out of whole cloth as
opposed to simply requiring licensure for CRISPR use through the state medical
board and USMLE passage.
Those who wish to practice medicine or conduct medical research on embryos,
using CRISPR technology, should go through the rigorous process of formal medical
education. It is quite easy to understand why public policy places a high degree of
importance on medical training for those who practice procedures such as in vitro
fertilization because complications for the baby and the mother can be very
serious.' To that end, the risk associated with CRISPR is arguably even higher and
thus requires at least the same amount of regulation that in vitro fertilization requires.
CRISPR modifications to the human genome may have the ability to impact
generations of humans, since modifications in the germline may be passed on to
offspring. Thus where in vitro fertilization has the potential to affect two lives (the
mother and the baby), CRISPR modifications may affect the evolution of
mankind.

03

Considering the enormous effects CRISPR could have on the global community,
it is crucial that only those with highly specialized skill sets and qualifications be
able to use CRISPR and implant the modified embryos into human wombs. Thus,
state medical boards are currently in the prime position to oversee training, licensure,
and board certifications for CRISPR and GME implantation. It is likely that such
practices will merge into other areas of obstetrics and fertility training in medical
school, residency programs, fellowships, and beyond. Such practice and procedure
will hopefully ensure that only the best and brightest have the ability to work on the
genetic modification of embryos, a task that will ultimately change the course of
human evolution.
B. Eugenics
During a talk at the International Summit on Human Gene Editing, held in 2015,
concerns arose over the possibility that CRISPR might be used to aid in eugenic
' Id
o Id ("[The] examination [is] designed to assess their ability to apply knowledge, concepts, and
principles of health and disease that constitute the basis for safe and effective patient care ... The USMLE
provides state medical boards with a common evaluation system for all licensure applicants. To assure the
continued relevance of the exam, the NBME uses basic science and clinical faculty from the nation's
medical schools as well as practicing physicians, some ofwhom serve on state medical boards, to generate
the examinations.").
1o See Mayo Clinic Staff In Vitro Fertilization (IVF), MAYO CLINIC (Mar. 22, 2018),
httpsJ/www.mayoclinic.org/tests-procedures/in-vitro-fertilization/about/pac-20384716
[https://perma.ce4FP5-PSZ8].
"oSee Regalado, supra note 5.
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practices.'" Eugenics is defined by Merriam-Webster Dictionary as "the practice or
advocacy of controlled selective breeding of human populations (as by sterilization)
to improve the population's genetic composition."t0 5 Daniel Kevles, a historian of
science from NYU, spoke openly at the gene editing summit about the risk of eugenic
practices involved in the use of CRISPR technology.'06 Kevles stated that prominent
American scientists were supporters of eugenic practices, even prior to the rise of
Nazi Germany.'o7 This is not surprising since the practice of eugenics had a notable
following in American culture prior to Nazi Germany and can be found in the
histories of many cultures throughout the world.'io Among those who endorsed
eugenics were men like Charles Davenport, who "founded the Eugenics Record
Office, which pursued eugenics research from 1910 to 1939[,]" and Alexander
Graham Bell who served on the board of the Eugenics Record Office.'" In an article
written by Tanya Lewis for Business Insider about the history of eugenics in relation
to CRISPR technology, Lewis stated that: "Eugenics was popularized in books and
articles, and newspaper headlines of the time heralded the 'era of supermen.' State
fairs held fitter family contests, where teams of doctors performed psychological and
physical exams on family members. The family with the highest eugenic health grade
was awarded a trophy.""o U.S. history is thus peppered with more than a mere silent
nod and wink at eugenic practices. Forced sterilization was sanctioned by numerous
states and even permitted by the Supreme Court in Buck v. Bell,"' where
"[e]ighteen-year-old Carrie Buck was ordered sterilized because she was deemed
'feeble-minded' after becoming pregnant.""I 2 These were the kind of laws that acted
as catalysts for similar policies throughout Europe, including in Nazi Germany,
during the 1930s."
Given the sordid history of eugenics in America, a less than upright use of
CRISPR technology is not unfathomable. During his talk at the gene editing summit,
Kevles argued that although modem Americans typically think of eugenic practices
with disdain, the possibility for such practices to re-emerge through CRISPR
technology is not unimaginable, and perhaps not far off." 4 Eugenic practices would
most likely sneak into modem society on a road paved with good intentions. Kevles
noted that "the economics of lowering medical costs, selection for races with a lower
risk of a particular disease, overconfidence in genes as the basis of bad traits, and
finally, consumer demand to improve ourselves" were all factors that could move
" See Tanya Lewis, The Major Concern About a Powrfid New Gene-editing Technique that Most
(Dec.
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the trajectory of CRISPR research and use in a direction that looks an awful lot like
modem day eugenics. "s
While concerns raised by the scientific community at the summit are clearly
valid, there is another way to analyze the gene selection technology afforded by
CRISPR. The above argument proposes that selecting for specific genes could lead
to eugenic practices which are akin to Nazi Germany. Of course, if the intention of
the scientists, or those utilizing the technology, is to wipe out specific races (or even
if that is the unintended effect), such practices should be banned and heavily
sanctioned. There is, however, another way to look at the gene selection practices
afforded by CRISPR. Truly, there is nothing new under the sun, and arguably parents
or scientists choosing to select for specific eye or hair colors, body types, or
intelligence, are just doing what humans have been doing for eons via sexual
selection. To that end, it would be a losing argument to say that humans were
inherently evil for choosing partners based on height, intelligence, skin tone, or other
superficial features. Such behavior could be classified as highly self-interested, or
merely classified as a way to sexually select for the healthiest offspring, but it would
be extreme to call such practices evil or racist in and of themselves.
In the same way, CRISPR technology could be seen as a way to merely
streamline the process of sexual selection-making the process more efficient than
it otherwise would be without the technology. CRISPR technology could be used in
both a positive and a negative way, but the use of CRISPR to select for specific genes
is not inherently evil. To that end, it would be naYve to think that there is no
possibility for a sinister, slippery slope down the road of eugenics by way of CRISPR
technology. Therefore, as the popularity and accuracy of CRISPR technology
increases, Congress should come up with a statute that regulates CRISPR
technology using similar reasoning and logic as that discussed by the Court in
Yick Wo v. Hopkins." 6
In Yick Wo, petitioners, who were of Chinese descent, brought suit after a law
was passed in San Francisco requiring all laundry mat owners whose shops were not
made out of brick or stone to file for permits in order to continue operating. " After
passage of the law, 200 Chinese applicants were denied permits; while 80
non-Chinese applicants were granted permits."' Moreover, when the petitioners
continued to operate their laundry mats without permits, they were fined, and subject
to punishment by imprisonment for failure to pay the fines." 9 Yick Wo filed a
petition for habeas corpus with the Supreme Court of California, which did not
answer whether petitioner's rights were infringed under the U.S. Constitution.'" The
Supreme Court granted cert to consider violations under the Constitution, and held
that the power granted to state officials to grant or deny permits based upon a "naked
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and arbitrary power to give or withhold consent" was far too broad and thus a
violation of the Fourteenth Amendment. 12 1
The Court reasoned that because 200 Chinese applicants were denied permits,
while 80 non-Chinese applicants were granted permits, the numbers spoke for
themselves, meaning there could be no other explanation for the outcome other than
discriminatory practices." Though the holding in Yick Wo was based upon the
Fourteenth Amendment, which makes any state practice of discrimination based
upon race illegal,123 a similar rule could be utilized by Congress and applied to any
CRISPR based procedures-whether privately or state sanctioned. Thus, any time
CRISPR is being used in a way that precludes any other explanation other than
discriminatory practices, such use must be found to be illegal, as an act of eugenic
practices.
CONCLUSION

CRISPR has serious potential to change the modem world. Before humanity can
embrace this technology, however, more research must be done, and regulations
must be implemented. Specifically, policy should allow for patents to be drawn to
CRISPR modified embryos, prior to implantation, in order to incentivize the best and
brightest to spend their time and resources on this evolution-altering research. Patent
law, however, must be modified in its application to human embryos by mandating
full exhaustion ofall property rights belonging to the patent holder upon implantation
or birth, so as not to violate the Thirteenth Amendment or the PTO's rule that it will
not issue patents drawn to human beings.1 24 Even still, patent law will not remedy all
of the safety and ethical concerns related to CRISPR technology. Thus, in the
absence of any significant regulation on CRISPR technology, the FDA is arguably
in the best position to regulate pre-implantation phases of CRISPR research since the
FDA already regulates other forms of gene therapy.1 25 Once CRISPR technology is
safe enough to use on viable human embryos, however, state medical boards should
regulate those who want to practice CRISPR procedures in the same way as other
medical practices. 126 Finally, while concerns over the ability of CRISPR technology
to be used in aiding eugenic practices is not entirely unwarranted, these concerns
should not be a complete roadblock in the advancement of this technology. As in
Yick Wo, where the numbers spoke for themselves, leading the court to conclude
there were indeed discriminatory practices occurring in San Francisco,' 27 so too
could Congress infer discriminatory practices by CRISPR practitioners simply by
looking at factors such as whether every embryo coming out of a specific clinic was
blue-eyed and blonde-haired, or whether that clinic turned away all embryos which
otherwise would not fit that description. Similar to the ultimate conclusion in Yick
Id at 365-66, 374.
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Wo, there are simple ways for courts or statutes to limit the scope of CRISPR use by
making illegal any use of CRISPR, whether private or not, which precludes any
possibility other than that CRISPR is being used in a discriminatory manner.

